ASSESSING CARDIOPROTECTIVE EFFECT OF ERYTHROPIOTEIN IN UREMIC CARDIOMYOPATHY THROUGH MODULATION OF NUCLEAR FACTOR KAPPA -β AND ASSOCIATD PROINFLAMMATORY CYTOKINES | ||||
Benha Medical Journal | ||||
Article 221, Volume 39, Special issue (Academic), September and October 2022, Page 141-152 PDF (1.19 MB) | ||||
Document Type: Original Article | ||||
DOI: 10.21608/bmfj.2021.36304.1291 | ||||
![]() | ||||
Authors | ||||
dania abdelhady mohamed ![]() | ||||
1physiology department -banha faculty of medecine- banha university | ||||
2Physiology Department, Faculty of Medicine, Benha University. | ||||
3Department of physiology,Faculty of medicine,Benha university,Benha 13518,QG,Egypt. | ||||
Abstract | ||||
Background: Chronic kidney disease is a global public health problem that shortens lifespan by increasing the risk of cardiovascular disease. Aim: This study aimed to investigate the cardioprotective effect of erythropiotein (EPO) on uremic cardiomyopathy (UCM) and targeting the possible role of NFκβ. Methods: UCM was induced surgically in rats via a one-step 5/6th nephrectomy procedure. Serum level of Urea and Creatinine were measured to assess renal function. Also, EF%, FS% , LVDd & LVSd were estimated to assess the cardiac function . Moreover, tissue level of NFκβ, IL1 , IL6 and TNFα were measured to assess the possible mechanism .Results: UCM caused a significant increase in urea , creatinine , IL1 , IL6 , TNFα ,NFκβ , LVDd & LVSd with a significant decrease in EF% & FS%. Administration of EPO caused a significant improvement of the aforementioned UCM effects. Conclusion, EPO has cardioprotective effect in UCM targeting NFκβ. | ||||
Keywords | ||||
CKD; EPO; UCM; nuclear factor kappa beta (NF-κβ) | ||||
Statistics Article View: 254 PDF Download: 351 |
||||